Trastuzumab biosimilar is under clinical development by Aprogen and currently in Phase III for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase III drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Trastuzumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Trastuzumab biosimilar overview
Trastuzumab biosimilar is under development for the treatment of HER2 positie breast cancer. It is administered via the intravenous route. The drug candidate is a humanized anti-HER2 monoclonal antibody that acts by targeting cells expressing tyrosine kinase type cell surface receptor HER2.
Aprogen is into the manufacture of equipment used in the steel, environmental, energy and chemical, and oil sand plant facilities. The company manufactures and supplies cokes, fired heaters, thermal sprays, wear plates and hard-facing products. It also offers thermal insulation works. The company operates in South Korea. Aprogen is head quartered in Seoul, South Korea.
For a complete picture of Trastuzumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.